Patent · US Active

Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms

US11117973B2 · kind B2 · utility

0Cited by

9References

39Claims

0Family size

Assignee

Inhibrx, Inc. · US

Inventors

John C. Timmer · Village of La Jolla, US
Kyle S. Jones · San Marcos, US
Amir S. Razai · Village of La Jolla, US
Abrahim Hussain · Village of La Jolla, US
Katelyn M. Willis · Village of La Jolla, US
Quinn Deveraux · Village of La Jolla, US
Brendan P. Eckelman · Village of La Jolla, US

Key dates

Filing date	Apr 18, 2019
Grant date	Sep 14, 2021
Priority date	—
Expiry date	Aug 23, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/75
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The disclosure relates generally to molecules that specifically engage death receptor 5 (DR5), a member of the TNF receptor superfamily (TNFRSF) and methods of treatment. More specifically the disclosure relates to multivalent and multispecific molecules that bind at least DR5.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.